EWA
FULC icon

EverSource Wealth Advisors’s Fulcrum Therapeutics FULC Stock Holding History

EverSource Wealth Advisors’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.14K Buy
409
+202
+98% +$1.87K ﹤0.01% 3479
2025
Q4 		$2.34K Buy
207
+3
+1% +$31 ﹤0.01% 3448
2025
Q3 		$1.88K Sell
204
-14
-6% -$101 ﹤0.01% 3536
2025
Q2 		$1.5K Buy
+218
New +$1.17K ﹤0.01% 3601

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
FTM
First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

EverSource Wealth Advisors's FULC Position: Q1 2026 in Review

EverSource Wealth Advisors increased its Fulcrum Therapeutics (FULC) stake by 98% in Q1 2026, buying an estimated $1.87K and bringing the position to 409 shares worth $3.14K. The position accounts for ﹤0.01% of the portfolio, ranked #3479.

EverSource Wealth Advisors first reported a position in FULC in Q2 2025 and has held it in 4 quarters since. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

  • EverSource Wealth Advisors held 409 shares of Fulcrum Therapeutics worth $3.14K as of Q1 2026.
  • EverSource Wealth Advisors bought 202 Fulcrum Therapeutics shares in Q1 2026, an estimated $1.87K.
  • Fulcrum Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q1 2026, its #3479 holding.
  • EverSource Wealth Advisors first reported a position in Fulcrum Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on EverSource Wealth Advisors's 13F filing for Q1 2026, filed 14 May 2026.